Desmond Yip

5.5k total citations
162 papers, 2.9k citations indexed

About

Desmond Yip is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Desmond Yip has authored 162 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Oncology, 59 papers in Pulmonary and Respiratory Medicine and 30 papers in Surgery. Recurrent topics in Desmond Yip's work include Colorectal Cancer Treatments and Studies (46 papers), Gastric Cancer Management and Outcomes (27 papers) and Genetic factors in colorectal cancer (21 papers). Desmond Yip is often cited by papers focused on Colorectal Cancer Treatments and Studies (46 papers), Gastric Cancer Management and Outcomes (27 papers) and Genetic factors in colorectal cancer (21 papers). Desmond Yip collaborates with scholars based in Australia, United Kingdom and United States. Desmond Yip's co-authors include Christos S. Karapetis, Peter Harper, Peter Gibbs, Craig Underhill, Christopher Steer, Yu Jo Chua, Niall C. Tebbutt, John Zalcberg, Richard Dowling and Derek J. Jonker and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Desmond Yip

157 papers receiving 2.8k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Desmond Yip 1.6k 938 579 498 398 162 2.9k
Mahmut Gümüş 2.2k 1.4× 1.2k 1.3× 466 0.8× 757 1.5× 376 0.9× 174 3.7k
Hope E. Uronis 1.5k 0.9× 848 0.9× 428 0.7× 628 1.3× 478 1.2× 119 2.3k
Monika Klinkhammer‐Schalke 1.4k 0.9× 552 0.6× 567 1.0× 616 1.2× 607 1.5× 171 2.9k
Yuanyuan Zhao 1.9k 1.1× 1.1k 1.2× 558 1.0× 475 1.0× 533 1.3× 162 3.0k
Howard J. Lim 1.1k 0.7× 593 0.6× 610 1.1× 383 0.8× 438 1.1× 184 2.3k
Wakiko Ajiki 1.2k 0.7× 877 0.9× 259 0.4× 728 1.5× 306 0.8× 66 2.7k
Tom Børge Johannesen 2.1k 1.3× 1.0k 1.1× 673 1.2× 671 1.3× 457 1.1× 89 3.8k
M. Marangolo 2.1k 1.3× 2.0k 2.2× 763 1.3× 946 1.9× 333 0.8× 132 4.1k
Ajay V. Maker 3.0k 1.8× 600 0.6× 826 1.4× 850 1.7× 292 0.7× 127 4.4k
Hirotoshi Hasegawa 2.9k 1.8× 1.3k 1.4× 538 0.9× 2.1k 4.1× 451 1.1× 175 4.6k

Countries citing papers authored by Desmond Yip

Since Specialization
Citations

This map shows the geographic impact of Desmond Yip's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Desmond Yip with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Desmond Yip more than expected).

Fields of papers citing papers by Desmond Yip

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Desmond Yip. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Desmond Yip. The network helps show where Desmond Yip may publish in the future.

Co-authorship network of co-authors of Desmond Yip

This figure shows the co-authorship network connecting the top 25 collaborators of Desmond Yip. A scholar is included among the top collaborators of Desmond Yip based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Desmond Yip. Desmond Yip is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Yip, Desmond, John Zalcberg, Jean‐Yves Blay, et al.. (2025). Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial. British Journal of Cancer. 132(10). 897–904. 1 indexed citations
3.
Yip, Desmond, et al.. (2024). External Validation of Risk Scores for Predicting Venous Thromboembolism in Ambulatory Patients with Lung Cancer. Cancers. 16(18). 3165–3165. 1 indexed citations
4.
Paterson, Catherine, et al.. (2024). “Pioneers, yes. We all should think that way” Improving Papua New Guinea Cancer Nurses Education through an International Partnership. Seminars in Oncology Nursing. 40(5). 151723–151723. 2 indexed citations
5.
Nagrial, Adnan, et al.. (2024). Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database of Systematic Reviews. 2024(12). CD011044–CD011044. 4 indexed citations
6.
Hicks, Sarah M., Teresa Neeman, Philip Choi, et al.. (2024). Response to COVID‐19 vaccination in patients on cancer therapy: Analysis in a SARS‐CoV‐2‐naïve population. Asia-Pacific Journal of Clinical Oncology. 20(3). 379–385. 1 indexed citations
7.
Kanjanapan, Yada, et al.. (2023). Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting. Technology in Cancer Research & Treatment. 22. 2223951017–2223951017.
8.
Yip, Desmond, et al.. (2022). Clinical predictors of survival in real world practice in stage IV melanoma. Cancer Reports. 6(2). e1691–e1691. 2 indexed citations
9.
Ward, Iain, et al.. (2021). A collaborative approach to meeting oncology challenges in island communities in the Asia‐Pacific region. Journal of Medical Imaging and Radiation Oncology. 65(4). 418–423. 1 indexed citations
10.
Naunton, Mark, et al.. (2021). Risk Factors and Prediction Models for Venous Thromboembolism in Ambulatory Patients with Lung Cancer. Healthcare. 9(6). 778–778. 9 indexed citations
11.
Naunton, Mark, et al.. (2021). Models for predicting venous thromboembolism in ambulatory patients with lung cancer: a systematic review protocol. BMJ Open. 11(12). e055322–e055322. 3 indexed citations
12.
Degeling, Koen, Hui‐Li Wong, Hendrik Koffijberg, et al.. (2020). Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data. PharmacoEconomics. 38(11). 1263–1275. 3 indexed citations
13.
Wu, Fan, Robert McCuaig, Christopher R. Sutton, et al.. (2019). Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer. International Journal of Molecular Sciences. 20(12). 3080–3080. 13 indexed citations
14.
Prasanna, Thiru, Fan Wu, Kum Kum Khanna, et al.. (2018). Optimizing poly (ADP‐ribose) polymerase inhibition through combined epigenetic and immunotherapy. Cancer Science. 109(11). 3383–3392. 29 indexed citations
15.
Beatty, Lisa, Emma Kemp, Jim Turner, et al.. (2016). Who Uses, and How Do They Benefit From, Online Psychotherapuetic Interventions for Cancer-Related Distress? An Outcomes Analysis of 'Finding My Way'. International Journal of Behavioral Medicine. 23. 1 indexed citations
16.
Beatty, Lisa, Emma Kemp, Tracey Wade, et al.. (2015). Finding My Way: uptake and satisfaction with an Internet self-help program for cancer-related distress. Psycho-Oncology. 24. 36–37.
17.
Chua, Yu Jo, Christopher Steer, & Desmond Yip. (2004). Recent advances in management of small-cell lung cancer. Cancer Treatment Reviews. 30(6). 521–543. 62 indexed citations
18.
Yip, Desmond, Christos S. Karapetis, A. H. Strickland, et al.. (2003). A dose-escalating study of oral eniluracil/5-fluorouracil plus oxaliplatin in patients with advanced gastrointestinal malignancies. Annals of Oncology. 14(6). 864–866. 7 indexed citations
19.
Yip, Desmond, et al.. (2001). COLLECTING DUCT CARCINOMA OF THE KIDNEY ASSOCIATED WITH THE SICKLE CELL TRAIT. International Journal of Clinical Practice. 55(6). 415–417. 3 indexed citations
20.
Karapetis, Christos S., et al.. (1999). THE TREATMENT OF METASTATIC COLORECTAL CANCER. International Journal of Clinical Practice. 53(4). 287–294. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mahmut Gümüş Breakdown of academic impact, for papers by Hope E. Uronis Breakdown of academic impact, for papers by Monika Klinkhammer‐Schalke Breakdown of academic impact, for papers by Yuanyuan Zhao Breakdown of academic impact, for papers by Howard J. Lim Breakdown of academic impact, for papers by Wakiko Ajiki Breakdown of academic impact, for papers by Tom Børge Johannesen Breakdown of academic impact, for papers by M. Marangolo Breakdown of academic impact, for papers by Ajay V. Maker Breakdown of academic impact, for papers by Hirotoshi Hasegawa
Rankless by CCL
2026